Dihexa Research Guide: HGF/c-Met & Synaptogenesis

What Is Dihexa?

Dihexa (research/developmental code PNB-0408) is a synthetic, metabolically stabilized oligopeptide — a modified tripeptide derived from the C-terminal active fragment of angiotensin IV (Ang IV). Its chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. The molecule is built on an Nle-Tyr-Ile Ang-IV-derived core, then capped at the N-terminus with a hexanoic (caproyl) group and finished with a 6-aminohexanoic amide tail. Those two modifications raise hydrophobicity and reduce hydrogen bonding, which is what reportedly confers oral activity, blood-brain-barrier permeability, and metabolic stability — the properties that distinguish dihexa from the rapidly cleaved parent peptide.

Dihexa is a single, defined small molecule, not a biologic. It was developed in the Joseph Harding / John Wright laboratory at Washington State University around 2011–2013 as a research tool for studying the growth-factor signaling believed to underlie synapse formation. As covered in the literature section below, that originating body of work later became the subject of a serious data-integrity finding, so this guide treats the foundational mechanistic claims with appropriate skepticism.

Proposed Mechanism of Action

Dihexa is described in the literature as a positive modulator / allosteric activator of the hepatocyte-growth-factor (HGF) — c-Met receptor tyrosine kinase system. Rather than acting as a direct c-Met agonist on its own, it is reported to bind HGF with high affinity and to augment c-Met (MET) autophosphorylation at otherwise subthreshold HGF concentrations — in other words, it is framed as potentiating HGF-dependent signaling rather than replacing it. Dihexa's parent scaffold, Nle1-AngIV, is reported to share this HGF/c-Met-dependent activity.

Downstream of c-Met, activation is linked to canonical pro-survival and pro-plasticity cascades. An independent 2021 mouse study attributed dihexa's effects to PI3K/AKT signaling, and the originating lab's work connected the compound to hippocampal spinogenesis (dendritic-spine formation) and synaptogenesis. The conceptual appeal is that a small, orally available, brain-penetrant molecule could amplify an endogenous growth-factor system involved in building synapses.

What the Research Literature Reports

Dihexa's evidence base is preclinical only — rodent and in vitro work — and it is materially complicated by research misconduct, which we state plainly rather than gloss over. Dihexa itself has never been tested in a registered human clinical trial. The findings below describe what specific published papers reported, with their integrity status noted; none of it is presented as a use indication for research-grade material.

The Foundational Pharmacology Paper (now flagged)

The paper that first defined dihexa — structurally modifying an Ang-IV-derived tripeptide into "N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide (dihexa)" and reporting it as orally active, BBB-permeant, and metabolically stabilized — is McCoy et al., Journal of Pharmacology and Experimental Therapeutics, 2013 (344(1):141–154). It reported that oral dihexa (2 mg/kg gavage) reversed scopolamine-induced spatial-memory deficits and improved Morris water maze performance in rats, with reported synaptogenic activity. This paper now carries a published Notice / Expression of Concern (data integrity), issued in 2021, so it must be cited with that caveat and not taken as clean evidence.

The Pivotal Mechanistic Paper (retracted)

The work asserting that dihexa and Nle1-AngIV bind HGF and that their procognitive/synaptogenic effects depend on HGF/c-Met activation — reporting c-Met phosphorylation, HGF-dependent cell scattering, and effects abolished by HGF/c-Met blockade — is Benoist et al., Journal of Pharmacology and Experimental Therapeutics, 2014 (351(2):390–402). This paper was retracted in April 2025 for falsified/fabricated figures. Washington State University found Leen H. Kawas and Joseph W. Harding responsible. We cite it here only as a cautionary, retracted source — its findings should not be treated as valid evidence for the HGF/c-Met-dependence claim.

The Strongest Still-Standing Result (independent)

The most meaningful currently-standing efficacy data point comes from an independent lab with no connection to Washington State University: Sun et al., Brain Sciences, 2021 (11(11):1487), from China Pharmaceutical University / Nanjing Medical University. In that study, oral dihexa (1.44 or 2.88 mg/kg over three months) rescued spatial learning and memory in 6-month-old APP/PS1 Alzheimer's-model mice, increased neuronal density and synaptophysin, and reduced markers of neuroinflammation (lower IL-1β/TNF-α, GFAP, and Iba-1; higher IL-10). The benefits were attributed to PI3K/AKT signaling and were reversed by the PI3K inhibitor wortmannin. This is real corroboration that the signal is not confined to the originating lab — but it is a single rodent study with no independent pharmacokinetic, safety, or toxicology data behind it.

Reconstitution & Handling for Research

Dihexa ships as a lyophilized / synthetic powder (100 mg jar) and must be brought into solution before use. The single most important practical fact about this compound is its solubility:

• It is highly lipophilic and poorly water-soluble. Unlike most injectable research peptides, dihexa generally does not dissolve well directly in water or bacteriostatic water. Published handling and supplier data indicate it is typically dissolved first in an organic co-solvent — most commonly DMSO (and in some protocols ethanol or PEG-type vehicles) — to make a stock solution, which can then be diluted into aqueous buffer for in vitro or in vivo work.
• Store cold, dry, and dark. Keep the sealed lyophilized powder desiccated and cold — typically −20 °C for long-term storage (refrigerated for short-term per the supplier COA), protected from light and moisture. Allow the vial to reach room temperature before opening to avoid condensation.
• Aliquot working solutions. Divide reconstituted stock to avoid repeated freeze-thaw cycles, and use within the supplier-stated window.

Because exact solubility, purity, and storage parameters vary by lot and vendor, the lot-specific Certificate of Analysis is the authoritative reference for any given vial. These are laboratory handling parameters only — not directions for human use. No human dosing is provided here because there is no validated human regimen for dihexa.

Dihexa vs Nle1-AngIV, BDNF & Fosgonimeton

Dihexa is frequently searched alongside several related compounds. They are not interchangeable, and the distinctions matter for any comparative research design.

Dihexa vs Its Parent, Nle1-AngIV

Nle1-AngIV (norleucine¹-angiotensin IV) and angiotensin IV itself are the precursors from which dihexa was engineered. Dihexa is the orally active, BBB-permeant, metabolically stabilized derivative — the capping modifications are precisely what the parent peptides lack. Both dihexa and Nle1-AngIV are reported to act through the same HGF/c-Met-dependent activity, with dihexa optimized for durability and brain penetration.

Dihexa vs BDNF

The contested "~10⁷-fold more potent than BDNF at spinogenesis" comparison is the headline claim most often attached to dihexa. As noted above, its origin is the concern-flagged Washington State University data, so it should be cited skeptically — it is not an established, independently replicated potency figure. BDNF is an endogenous neurotrophin acting through TrkB; the dihexa-vs-BDNF framing is a marketing artifact more than a settled scientific comparison.

Dihexa vs Fosgonimeton (ATH-1017)

This is the comparison that matters most for translational expectations. Fosgonimeton (ATH-1017 / NDX-1017, developed by Athira Pharma) is a related but separate molecule — an HGF/MET positive modulator built on similar chemistry — that actually reached human trials. It failed its primary endpoints in Phase 2 ACT-AD, Phase 2/3 LIFT-AD (Alzheimer's), and Phase 2 SHAPE (dementia with Lewy bodies / Parkinson's), and the program was discontinued in 2024. Dihexa is not fosgonimeton, but the failure of the clinically tested successor chemistry is a sobering, negative-to-unproven translational signal that should temper any optimism drawn from the rodent data.

A Note on Other "Nootropic" Research Peptides

Researchers sometimes cross-shop dihexa with other synaptogenic or neuroactive research compounds such as cerebrolysin, Semax/Selank, or CNTF-derived peptides. These act through different pathways and are not mechanistically equivalent to dihexa's proposed HGF/c-Met route — a distinction worth keeping straight when designing comparisons.

Evaluating Research-Grade Dihexa Supply

For reproducible work, the supply chain matters as much as the compound — and for a molecule with this much surrounding hype and a known data-integrity history, careful sourcing is especially important. When evaluating dihexa for research, look for:

1. A Batch-Specific Third-Party COA

A legitimate vendor provides a Certificate of Analysis for each lot, ideally generated by an independent lab. For dihexa, the COA should report:

• HPLC purity — research-grade material should test high (≥98%, ideally ≥99%), with a clean chromatogram.
• Mass-spec confirmation — verifying the measured mass matches the expected molecular weight (~504.66 g/mol for formula C₂₇H₄₄N₄O₅), which is how you confirm you actually received the correct molecule and not a mislabeled or incorrect-formula product. This matters here because incorrect formula/MW figures circulate for dihexa online.
• Batch / lot number and a recent test date linking the COA to your specific jar, plus lot-specific solubility and storage notes given the co-solvent handling.

Elytra Labs publishes batch-specific third-party COAs for every research compound we ship. Browse our current COA library → and see our guide to reading a peptide COA for how to interpret the chromatogram and mass-spec data.

2. Proper Form and Cold-Chain Discipline

Dihexa should arrive as a lyophilized / synthetic powder. Keep it cold, dry, and sealed until use, and prepare stock solutions in an appropriate organic co-solvent per the lot COA. A vendor that ships it correctly and documents handling guidance — including the solubility caveat — is doing real quality control, not just shipping powder.

Frequently Asked Research Questions

What is dihexa and where did it come from?

Dihexa (PNB-0408) is a synthetic angiotensin-IV-derived oligopeptide — chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, CAS 1401708-83-5, formula C₂₇H₄₄N₄O₅, MW ~504.66. It was developed in the Joseph Harding / John Wright lab at Washington State University around 2011–2013 as an orally active, blood-brain-barrier-permeant, metabolically stabilized Ang-IV analog for studying synapse formation.

What is dihexa's proposed mechanism?

The proposed mechanism is positive modulation of the HGF/c-Met receptor system, with downstream PI3K/AKT signaling linked to dendritic-spine formation (spinogenesis) and synaptogenesis in lab models. Importantly, the specific HGF/c-Met-dependence claim rests on a retracted paper (Benoist et al., 2014), so it should be regarded as the originating lab's proposed mechanism rather than settled fact.

Has dihexa been tested in humans?

No. All dihexa evidence is preclinical — rat and APP/PS1 mouse models plus in vitro assays. There are no human clinical trials of dihexa itself. Separately, a related but distinct molecule, fosgonimeton (ATH-1017), reached human trials and failed its Phase 2/3 Alzheimer's and dementia endpoints; that program was discontinued in 2024.

Is the "10 million times more potent than BDNF" claim real?

It should be treated as unverified. That figure originates from the same Washington State University work that is now retracted (Benoist et al., 2014) or flagged with a Notice of Concern (McCoy et al., 2013), where image manipulation by Kawas and Harding was found. It is a widely repeated marketing line, not an independently replicated, established potency measurement.

Why is dihexa hard to reconstitute?

Because it is highly lipophilic and poorly water-soluble, dihexa typically will not dissolve well directly in bacteriostatic water. It is usually prepared in an organic co-solvent such as DMSO to make a stock solution first, which is then diluted into aqueous buffer. Always check the lot-specific COA for the recommended solvent, concentration, and storage parameters.